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ABSTRACT
Objective: This study aimed to determine the potential inhibitory effects of Eleutherine bulbosa on the growth of Plasmodium falciparum and its toxic 
effects on lymphocyte cells.
Methods: We performed a 50% inhibition concentration (IC50) test of E. bulbosa against P. falciparum, used transmission electron microscopy (TEM) 
to observe Plasmodium morphology after exposure to E. bulbosa, and determined E. bulbosa’s cytotoxic concentration 50% (CC50) against lymphocytes.
Results: The IC50 value of E. bulbosa was 0.62 μg/ml. We observed crystals in the mitochondria of parasites under TEM. CC50 values at 24 h and 72 h 
were 851.14 μg/ml and 707.94 μg/ml, respectively.
Conclusion: The main content of E. bulbosa is naphthoquinones that are suspected of having a mitochondrial target on the malaria parasite. E. bulbosa 
is not toxic to lymphocytes; therefore, it has a potential as an antimalarial therapeutic.
Keywords: Eleutherine bulbosa, Antimalarial, Toxicity, 50% Inhibition concentration.
INTRODUCTION
Malaria is a life-threatening disease that has killed many children aged 
<5 years and pregnant women [1]. Globally, the number of malaria 
cases decreased by 18% from 262 million cases in 2000 to 214 million 
cases in 2015, whereas the mortality rate decreased by 48% from 
839,000 cases in 2000 to 438,000 cases in 2015 [2]. Although malaria 
prevalence appears to be decreasing, the emergence of parasites that 
are resistant to antimalarial drugs and vector resistance to insecticides 
does threaten this trend. Therefore, drug efficacy should be monitored 
periodically because new therapies should be developed [3].
Currently, the standard method for malaria treatment in Indonesia is 
artemisinin-based combination therapy [4]. However, the strains of 
Plasmodium falciparum which are resistant to artemisinin have been 
detected in five countries in the Mekong region, including Cambodia, 
Laos, Myanmar, Thailand, and Vietnam [2]. To overcome the problem of 
resistance to antimalarial drugs, looking at the history of the discovery 
of quinine from the cinchona tree and artemisinin from Artemisia 
annua L. (Asteraceae) may lead to the discovery of new antimalarial 
drugs derived from plants [5].
Research to obtain new antimalarial drugs, either synthetic or 
sourced from natural ingredients, from plants is currently being 
performed. A study conducted by Widyawaruyanti and Zaini reported 
that dichloromethane extract obtained from Artocarpus champeden 
stem bark could inhibit the growth of P. falciparum with an IC50 of 
0.99 μg/ml. This plant contains compounds such as flavonoids that 
have antimalarial activity. Flavonoids are suspected to be able to 
inhibit the growth of P. falciparum through the following two main 
mechanisms: (1) New permeation pathways, by inhibiting the nutrient 
transport for parasites, and (2) inhibiting hemoglobin degradation and 
heme detoxification in parasite food vacuoles [6]. In another study that 
used methanol extract obtained from Averrhoa bilimbi L. leaves, it was 
reported to be able to inhibit the growth of P. falciparum with an IC50 
of 2.805 μg/ml. A. bilimbi L. leaves contain many luteolin compounds, 
which are flavonoids. Luteolin shows potential in inhibiting the fatty 
acid biosynthesis I (FabI) Plasmodium enzyme. The FabI enzyme is a 
part of fatty acid synthase Type II, also known as enoyl-ACP reductase, 
and is involved in the final stage of the elongation of the Plasmodium 
fatty acid chain [7].
Eleutherine bulbosa (Miller) Urban is a plant belonging to the 
Iridaceae family that originates from South America; this plant 
is widely grown in Asia and Africa [8]. In Indonesia, this plant is 
known as dayak onion and is planted in Kalimantan, where the local 
population uses it as a traditional medicine for the treatment of breast 
cancer, heart disease, tumors, inflammation, and bleeding and as an 
immunostimulant [9]. E. bulbosa tubers are known to contain many 
naphthoquinones and its derivatives such as elecanacine, eleutherol, 
eleutherine, and eleutherinone. In addition, E. bulbosa tubers contain 
alkaloids, steroids, glycosides, flavonoids, phenolics, saponins, 
triterpenoids, tannins, and quinones [10]. Allegedly, the mechanism of 
the inhibition of P. falciparum growth is similar to that of atovaquone, 
an antimalarial drug containing hydroxynaphthoquinones, because 
the main content of E. bulbosa comprises compounds belonging to the 
naphthoquinone group. Hydroxynaphthoquinones act as competitive 
inhibitors of ubiquinol, especially by inhibiting the electron transport of 
Plasmodium mitochondria in the bc1 complex [11]. Studies on E. bulbosa 
as an antibiotic and anticancer drug have been widely conducted, but 
those on E. bulbosa as an antimalarial agent are rare. Therefore, we are 
interested in examining E. bulbosa as an antimalarial agent by testing 
its antimalarial activity with a 50% inhibition concentration test (IC50), 
analyzing the inhibition target of E. bulbosa through the observation 
of Plasmodium morphology with transmission electron microscopy 
(TEM), and testing its toxic effects against lymphocyte cells with a 50% 
cytotoxic concentration (CC50) test.
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METHODS
Preparation of sample
The sample used was E. bulbosa which was obtained from the 
Department of Pharmacology, Faculty of Medicine, University of 
Indonesia. Dimethyl sulfoxide was added to the sample, which was then 
vortexed until completely dissolved.
Preparation of P. falciparum parasite culture
The P. falciparum parasite used was from the 3D7 strain, originated from 
Tokyo University, Japan (routinely cultured at the Eijkman Molecular 
Biology Institute). The parasite was cultured in Roswell Park Memorial 
Institute 1640 medium containing 10% AB serum until the percentage 
of parasitemia reached 2% with a hematocrit level of 3%. The culture 
was performed using the Trager and Jensen procedure.
IC50 test
The test was performed using a 96-microwell plate; 180 μl of parasite 
culture was added to each well. The first well containing the control sample 
was not given any treatment. In the last well, 20 μl of the sample was added 
and gradual dilution performed up to second well. The microwell plate 
was inserted into a jar candle and kept in an incubator at 37°C for 48 h. 
After incubation, the plate was taken out of the candle jar, the medium was 
removed, and a thin blood smear was made from the sediment, followed by 
staining with 10% Giemsa. The percentage of parasitemia was calculated 
using a light microscope with 1000× magnification. To determine the IC50, 
a graph was created using Microsoft Excel.
Preparation of TEM sample
TEM samples used parasite cultures with 5% parasite and 3% hematocrit 
level. Overall, 900 ml of the parasite culture was added into each well of 
the 24-microwell plate. The first well containing the control sample was 
not treated; to the second well, 20 μl of the E. bulbosa sample with IC50 
concentration was added. Then, it was incubated in a candle jar at 37°C 
for 48 h. After the incubation period, the solution was transferred into 
a 1.5 ml tube and centrifuged to remove the supernatant. The sediment 
was washed by adding 500 μl of cacodylate buffer and homogenized. 
It was then left to stand for 15 min at 4°C and shaken using the shaker, 
followed by centrifugation. The washing process was repeated 3 times, 
followed by incubation of the homogenate for 48 h at 4°C with shaking.
Preparation of TEM block sample
At this stage, the sediment was added with 500 μl of glutaraldehyde 
(2.5%) and then homogenized and stored for 48 h at 4°C with shaking. 
It was then centrifuged at 3000 rpm for 5 min, the supernatant 
was removed, and the sediment was washed with 500 μl of buffer 
cacodylate 0.1 M + 3% sucrose, shaken for 15 min at 4°C, centrifuged at 
3000 rpm for 5 min, and then washed 3 times. Then, the sediment was 
supplemented with 500 μl 2% osmium tetroxide and 2.5% K3Fe(CN)6, 
incubated for 2 h at 4°C with shaking, and then washed with cacodylate 
buffer 0.1 M and 3% sucrose 3 times. Dehydration was performed 
using gradual concentration ethanol. After the dehydration stage, the 
sediment was infiltrated by adding 500 μl of pure propylene oxide and 
incubated for 1 h at room temperature. Furthermore, the processes 
of embedding, cutting, and coloring were performed to prepare the 
sample for observation by TEM.
Isolation and preparation of lymphocyte cells
Blood was added into a tube containing ethylenediaminetetraacetic 
acid; the lymphocyte cells were isolated using Ficoll gradient reagent. 
The lymphocyte cell sediment was supplemented with 1 ml of complete 
medium (Dulbecco’s Modified Eagle Medium, 10% fetal bovine serum, 
and 1% Penicillin-Streptomycin) and stained with trypan blue; the 
lymphocyte cell number was calculated with a hemocytometer. The 
lymphocyte cell solution was prepared with a density of 100,000 
cells/200 μl.
CC50 test
Five wells (96-microwell plates) were inoculated with 180 μl of 
lymphocyte cell stock solution. The well 1 (control) was left untreated. 
To wells 2, 3, 4, and 5, 20 μl of E. bulbosa with concentrations of 10−2, 
10−4, 10−6, and 10−8 was added, respectively. Homogenization was then 
carried out. Two plates were made along with a duplicate for each plate. 
Plate 1 was incubated in an incubator at 37°C, CO2 5% for 24 h, whereas 
plate 2 was incubated for 72 h. After the incubation period, the solution 
from each well was transferred into 1.5 ml tubes and centrifuged at 
1200 rpm for 10 min, the supernatant was removed, 200 μl PBS was 
added, and the sample was homogenized. Next, 10 μl of solution was 
taken and stained with trypan blue; the living and dead cells were 
enumerated using hemocytometer. The percentage cell viability was 
calculated using the following formula:
Number of living cells/total number of cells × 100%.
RESULTS
Analysis of the potential of E. bulbosa in the inhibition of 
P. falciparum growth
The result of the IC50 test of E. bulbosa on the growth of P. falciparum is 
presented in Table 1 and Fig. 1.
The IC50 concentration of E. bulbosa was determined to be 0.62 μg/ml.
Observation of P. falciparum morphology under TEM
The morphological differences of untreated and treated P. falciparum 
parasites are observed in Figs. 2 and 3.
Analysis of the toxicity effect of E. bulbosa on lymphocyte cells
In the toxicity test of E. bulbosa, lymphocyte cells were used because 
blood is exposed to chemical compounds/drugs consumed. Therefore, 
lymphocyte cells are often used by researchers to determine the toxic 
effects of a new chemical and drug compound [12].
In this test, lymphocyte cells with a density of 100,000 cells per well 
were incubated with E. bulbosa for 24 and 72 h. These two different 
incubation conditions were used to determine whether the toxic effects 
were affected only by the magnitude of the compound concentration 
or also affected by the duration of exposure to the compound. The 
concentrations of E. bulbosa used were 336.7 μg/ml, 3.367 μg/ml, 
3367×10−5 μg/ml, and 3367×10−7 μg/ml. For these concentrations, 
the cell viability percentages obtained after incubation for 24 h were 
89.78%, 97.48%, 99.165%, and 100%, respectively. From the results, 
the CC50 value was not obtained because the highest cell viability 
percentage obtained was 89.78%. Incubation for 72 h with the same 
concentrations of E. bulbosa resulted in the following cell viability 
percentages of 84.865%, 90.64%, 92.23%, and 93.75%, respectively. 
At the highest concentration of 336.7 μg/ml, the percentage of cell 
viability obtained was 84.865. By comparing the means of the 24-h 
and 72-h incubation groups by t-test using Microsoft Excel, P value 
obtained was 0.02 (p<0.05); this denoted that there was a significant 
difference between the two groups. The test was repeated with higher 
concentrations of 3367 μg/ml, 2694 μg/ml, 2020 μg/ml, and 1347 μg/
ml because CC50 had not been determined. The cell viability percentages 
after incubation for 24 h were 21.62%, 23.08%, 30.56%, and 37.5% 
for concentrations 336.7 μg/ml, 3.367 μg/ml, 3367 × 10−5 μg/ml, and 
Table 1: IC50 of E. bulbosa 
Concentration (µg/ml) % Parasitemia % Growth % Inhibition
0 3.8 100.0 0.0
3.367×1− 5 2.8 74.3 25.7
0.0003367 2.5 65.9 34.1
0.003367 2.3 61.1 38.9
0.03367 2.1 54.9 45.1
0.3367 2.0 52.2 47.8
3.367 1.7 46.0 54.0
33.67 1.3 35.0 65.0
336.7 0.7 18.6 81.4
3367 0.0 0.0 100.0
IC50: 50% inhibition concentration, E. bulbosa: Eleutherine bulbosa
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3367×10−7 μg/ml, respectively. After incubation for 72 h, the percentages 
of cell viability were 4.62%, 17.02%, 21.74%, and 23.91% for the 
abovementioned concentrations, respectively. The CC50 value after 24 h 
was 851.14 μg/ml and after 72 h was 707.94 μg/ml (Tables 2-5 and 
Figs. 4 and 5).
DISCUSSION
Many studies have used E. bulbosa as an antibiotic and anticancer agent, 
but research on E. bulbosa as an antimalarial is still very rare. Therefore, 
this study was conducted to determine the antimalarial potential, 
Fig. 1: A 50% inhibition concentration graph of the effect of Eleutherine bulbosa on Plasmodium falciparum
Fig. 2: The morphology of Plasmodium falciparum (control 
group). The mitochondria of the parasite can be seen with 
crystals in it (blue arrow)
Fig. 3: The morphology of Plasmodium falciparum after exposure 
to Eleutherine bulbosa at a concentration of 0.62 µg/ml for 48 h. 
The mitochondria are seen without crystals (m)
Table 2: CC50 of E. bulbosa to lymphocyte cells after 24 h






CC50: 50% cytotoxic concentration, E. bulbosa: Eleutherine bulbosa
Table 3: CC50 of E. bulbosa at higher concentrations to 
lymphocyte cells after 24 h





CC50: 50% cytotoxic concentration, E. bulbosa: Eleutherine bulbosa
Table 4: CC50 of E. bulbosa to lymphocyte cells after 72 h






CC50: 50% Cytotoxic concentration, E. bulbosa: Eleutherine bulbosa
Int J App Pharm, Vol 11, Special Issue 1, 2019
 Sesotyaning et al. 
 The 3rd International Conference on Global Health (ICGH), Universitas Indonesia, Bali, Indonesia 175
work mechanism, and toxicity effect of E. bulbosa. To determine the 
antimalarial potential of this plant, a IC50 test was conducted. In other 
studies, experiments have been conducted with methanol extract of 
srikaya leaves (Annona squamosa) as antimalarial agents, and the IC50 
value was found to be 2 μg/ml; an IC50 value of 4.9 μg/ml was obtained 
with the Zanthoxylum zanthoxyloides extract [13] and 22 μg/ml with the 
root chloroform extract was obtained from Andrographis paniculata. 
According to Basco et al. and Dolabela et al., criteria of in vitro 
Fig. 4: A 50% cytotoxic concentration graph of Eleutherine bulbosa to lymphocyte cells after 24 h
Fig. 5: A 50% cytotoxic concentration graph of Eleutherine bulbosa to lymphocyte cells after 72 h
Table 5: CC50 of E. bulbosa at higher concentrations to 
lymphocyte cells after 72 h





CC50: 50% cytotoxic concentration, E. bulbosa: Eleutherine bulbosa
antimalarial activity can be divided as follows: IC50 <10 μg/ml which 
denotes good activity, IC50 10–50 μg/ml which denotes medium activity, 
IC50 50–100 μg/ml which denotes low activity, and IC50 >100 μg/ml 
which denotes no antimalarial activity [7]. According to these criteria, 
E. bulbosa confers good antimalarial activity. Compared with the IC50 
value of the dichloromethane extract obtained from A. champeden stem 
bark (IC50 = 0.99 μg/ml), it is evident that antimalarial activities of 
E. bulbosa are higher (IC50 = 0.62 μg/ml).
One way to understand the mechanism of a drug or a compound is to 
observe the cell morphology of cells affected by the substance using 
a transmission electron microscope (TEM). TEM has been shown 
to be useful in the analysis of all cellular components, including the 
cytoskeleton, membrane system, organelles, cilia, and the special 
structures involved in cellular development, such as microvilli and 
synaptonemal complexes [14]. In this study, the morphology of malarial 
parasites was observed using culture samples of P. falciparum that 
had been exposed to E. bulbosa at a concentration of IC50 that was 
equal to 0.62 μg/ml and compared with cells that had been exposed 
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to a negative control sample. In the control samples, a mitochondrial 
form of Plasmodium with crystals was observed, whereas, in the 
treated samples, Plasmodium mitochondria without crystals were 
observed. This occurred possibly as a result of the inhibition of 
electron transport to the parasite mitochondria. E. bulbosa contains 
many naphthoquinone compounds, and these compounds have been 
shown to have antimalarial activity. A synthetic compound of the 
naphthoquinone group, hydroxynaphthoquinone, has been shown 
to have an antimalarial activity with a mechanism of inhibiting the 
electron transport of Plasmodium mitochondria in complex bc1 [11]. 
From the parasite mitochondrial observations, it was seen that the 
target of E. bulbosa was on the parasite mitochondria.
CONCLUSION
E. bulbosa has potential as an antimalarial agent with an IC50 value 
of 0.62 μg/ml with an inhibition target in the parasite mitochondria. 
The concentration of E. bulbosa cytotoxic to lymphocyte cells at 24 h 
incubation was found to be 851.14 μg/ml and at 72 h incubation was 
707.94 μg/ml.
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